Bristol Myers Squibb Co. (BMS) (NYSE: BMY)

https://www.bms.com

LinkedIn: https://www.linkedin.com/company/bristol-myers-squibb

Bristol Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. For more information about Bristol Myers Squibb, visit us at BMS.com or follow us on LinkedIn, Twitter, YouTube, Facebook and Instagram. Celgene and Juno Therapeutics are wholly owned subsidiaries of Bristol-Myers Squibb Company. In certain countries outside the U.S., due to local laws, Celgene and Juno Therapeutics are referred to as, Celgene, a Bristol Myers Squibb company and Juno Therapeutics, a Bristol Myers Squibb company. *

	Start	1989-10-04 merged
	Group	Bristol Myers Squibb (BMS) (Group)
	Industry	pharmaceutical

	Region	New York, NY
	Country	United States (USA)
	Street	430 East 29th Street 14th Floor
	City	10016 New York, NY
	Tel	+1-212-546-4000
		Address record changed: 2024-01-05

Basic data	Employees	H: 10,001 to 50,00 (2018-12-31)
	Currency	USD
	Annual sales	22,561,000,000 (revenue, total, consolidated (2018) 2018-12-31)
	Profit	4,947,000,000 (2018-12-31)
	Cash	6,911,000,000 (2018-12-31)

		* Document for »About Section«:

		Record changed: 2025-05-10

Picture Berlin Partner BIO 2025 International Convention Boston 650x200px

More documents for Bristol Myers Squibb (BMS) (Group)

To subscribe to our free, monthly mass spectrometry newsletter, please send an e-mail to info@iito.de and simply fill the subject line with the word »MSC Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the Eurpean life sciences and the life sciences in German-speaking Europe (DE, AT & CH) at Life-Sciences-Germany.com and Life-Sciences-Europe.com